Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies
Ontology highlight
ABSTRACT: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies
PROVIDER: PRJNA497449 | ENA |
REPOSITORIES: ENA
ACCESS DATA